Abstract
Azathioprine (AZA) is recognized among immunosuppressive medications as relatively safe during pregnancy for women with systemic lupus erythematosus (SLE) requiring aggressive treatment. This pilot study aimed to determine whether SLE therapy during pregnancy was associated with developmental delays in offspring.
Original language | English |
---|---|
Pages (from-to) | 759-66 |
Number of pages | 8 |
Journal | Arthritis Care & Research |
Volume | 65 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2013 |
Bibliographical note
Copyright © 2013 by the American College of Rheumatology.Keywords
- Adolescent
- Adult
- Azathioprine
- Child
- Child, Preschool
- Cohort Studies
- Developmental Disabilities
- Education, Special
- Female
- Humans
- Infant
- Lupus Erythematosus, Systemic
- Male
- Pilot Projects
- Pregnancy
- Pregnancy Complications
- Prenatal Exposure Delayed Effects